P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL

• Arnon Kater,
• Brandon Hodkinson,
• Carol Moreno,
• Talha Munir,
• Mark-David Levin,
• Carsten Niemann,
• Keqin Qi,
• Pierre Sinet,
• Kurt Baeten,
• Donne Bennett Caces,
• Srimathi Srinivasan

Affiliations

Arnon Kater

1 Amsterdam Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

Brandon Hodkinson

2 Oncology Translational Research, Janssen Research & Development, Spring House, United States

Carol Moreno

3 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Talha Munir

4 St James’s Hospital, Leeds, United Kingdom

Mark-David Levin

5 Albert Schweitzer Hospital, Department of Internal Medicine, Dordrecht, The Netherlands

Carsten Niemann

6 Rigshospitalet, Copenhagen University Hospital, Department of Hematology, Copenhagen, Denmark

Keqin Qi

7 Janssen Research & Development, Titusville, United States

Pierre Sinet

8 Janssen Research & Development, Bridgewater, United States

Kurt Baeten

9 Janssen Research & Development, Beerse, Belgium

Donne Bennett Caces

10 Janssen Research & Development, Raritan, United States

Srimathi Srinivasan

11 Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, United States